Directori de persones
Antonia Salud Salvia

Antonia Salud Salvia

Grau: Doctor/a


masalud.lleida.ics(ELIMINAR)@gencat.cat

Grups

Publicacions

  • Sorolla MA; Sorolla A; Parisi E; Salud A; Porcel JM

    Diving into the Pleural Fluid: Liquid Biopsy for Metastatic Malignant Pleural Effusions.

    Cancers 13 -. .

    [doi:10.3390/cancers13112798]

  • Porcel JM; Murata P; Porcel L; Bielsa S; Pardina M; Salud A

    Prevalence, clinical characteristics, and outcome of pleural effusions in ovarian cancer.

    Pleura and Peritoneum 6 75-81. .

    [doi:10.1515/pp-2020-0152]

  • Vidal, J; Casadevall, D; Bellosillo, B; Pericay, C; Garcia-Carbonero, R; Losa, F; Layos, L; Alonso, V; Capdevila, J; Gallego, J; Vera, R; Salud, A; Martin-Richard, M; Nogue, M; Cillan, E; Maurel, J; Faull, I; Raymond, V; Fernandez-Martos, C; Montagut, C

    Clinical Impact of Presurgery Circulating Tumor DNA after Total Neoadjuvant Treatment in Locally Advanced Rectal Cancer: A Biomarker Study from the GEMCAD1402 Trial

    CLINICAL CANCER RESEARCH 27 2890-2898. .

    [doi:10.1158/1078-0432.CCR-20-4769]

  • Sastre, J; Garcia-Alfonso, P; Vieitez, JM; Cano, MT; Rivera, F; Reina-Zoilo, JJ; Salud-Salvia, A; Quintero, G; Robles-Diaz, L; Safont, MJ; La Casta, A; Gil, S; Polo, E; Asensio-Martinez, E; Garcia-Paredes, B; Lopez, RL; Guillot, M; Valladares-Ayerbes, M; Aranda, E; Diaz-Rubio, E

    Influence of BRAF and PIK3CA mutations on the efficacy of FOLFIRI plus bevacizumab or cetuximab as first-line therapy in patients with RAS wild-type metastatic colorectal carcinoma and < 3 baseline circulating tumour cells: the randomised phase II VISNU-2 study

    ESMO Open 6 -. .

    [doi:10.1016/j.esmoop.2021.100062]

  • Morales Murillo, Serafin; Gasol Cudos, Ariadna; Veas Rodriguez, Joel; Canosa Morales, Carles; Melé Olivé, Jordi; Vilardell Villellas, Felip; Sanchez Guzman, Douglas Rene; Iglesias Martínez, Edelmiro; Salud Salvia, Antonieta

    Selection of neoadjuvant treatment based on the 21-GENE test results in luminal breast cancer

    BREAST 56 35-41. .

    [doi:10.1016/j.breast.2021.01.001]

  • Murillo, SM; Cudos, AG; Rodriguez, JV; Morales, CC; Olive, JM; Villellas, FV; Guzman, DRS; Martinez, EI; Salvia, AS

    Survival analysis of bevacizumab plus taxane treatment in luminal metastatic breast cancer

    Future Science Oa 7 -. .

    [doi:10.2144/fsoa-2020-0146]

  • Valdivia, AA; Salva, F; Ros, J; Baraibar, I; Martinez, GA; Gonzalez, NS; Garcia, A; Margalef, NM; Urteaga, JLC; Capdevila, J; Salvia, MAS; Paez, D; Casado, E; Comas, R; Ruiz-Pace, F; Javierre, GV; Eyzaguirre, DAA; Dienstmann, R; Fernandez, MEE; Tabernero, J

    Spotlight on refractory metastatic colorectal cancer (refMCRC): Role of prognostic characteristics in the continuum of care

    ANNALS OF ONCOLOGY 32 547-548. .

    [doi:10.1016/j.annonc.2021.08.947]

  • Benavides, M; Gomez-Espana, A; Garcia-Alfonso, P; Garcia, C; Vieitez, JM; Sureda, BM; Rivera, F; Aguilera, MJS; Esteve, AA; Ortega, MG; Valladares-Ayerbes, M; Mena, AC; Gonzalez-Flores, E; Robles, L; Salvia, AS; Alonso, V; Viladot, CM; Asensio-Martinez, E; Diaz-Rubio, E; Aguilar, EA

    Upfront primary tumour resection (UPTR) and survival in synchronous metastatic colorectal cancer according to primary tumour location and RAS status: Pooled analysis of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)

    ANNALS OF ONCOLOGY 32 544-544. .

    [doi:10.1016/j.annonc.2021.08.939]

  • Valladares-Ayerbes, M; Safont, MJ; Gonzalez-Flores, E; Garcia-Alfonso, P; Aguilar, EA; Munoz, AML; Nogueras, LC; Ferrer, EF; Salas, NR; Aparicio, J; Llanos, M; Trujillo, OAC; Caceres, PP; Cruz-Hernandez, JJ; Fernandez, MS; Salvia, AS; Garcia-Carbonero, R; Sureda, BM; Conesa, MAV; Vila, AL

    Concordance of baseline RAS mutational status (ms) between tissue and cell-free DNA (cfDNA) and association with overall response rate (ORR) in first-line (1L) metastatic colorectal cancer (mCRC) patients (pts): PERSEIDA study (cohort 2) (NCT02792478)

    ANNALS OF ONCOLOGY 32 560-560. .

    [doi:10.1016/j.annonc.2021.08.976]

  • Parisi E; Sorolla A; Montal R; González-Resina R; Novell A; Salud A; Sorolla MA

    Prognostic Factors Involved in the Epithelial-Mesenchymal Transition Process in Colorectal Cancer Have a Preponderant Role in Oxidative Stress: A Systematic Review and Meta-Analysis.

    Cancers 12 1-28. .

    [doi:10.3390/cancers12113330]

  • Aranda E; Viéitez JM; Gómez-España A; Gil Calle S; Salud-Salvia A; Graña B; Garcia-Alfonso P; Rivera F; Quintero-Aldana GA; Reina-Zoilo JJ; González-Flores E; Salgado Fernández M; Guillén-Ponce C; Garcia-Carbonero R; Safont MJ; La Casta Munoa A; García-Paredes B; López López R; Sastre J; Díaz-Rubio E

    FOLFOXIRI plus bevacizumab versus FOLFOX plus bevacizumab for patients with metastatic colorectal cancer and =3 circulating tumour cells: the randomised phase III VISNÚ-1 trial.

    ESMO Open 5 -. .

    [doi:10.1136/esmoopen-2020-000944]

  • Camps Herrero, C; Batista, N; Diaz Fernandez, N; Escobar Alvarez, Y; Gonzalo Gomez, A; Isla Casado, D; Salud, A; Terrasa Pons, J; Guillem Porta, V

    Breakthrough cancer pain: review and calls to action to improve its management

    CLINICAL & TRANSLATIONAL ONCOLOGY 22 1216-1226. .

    [doi:10.1007/s12094-019-02268-8]

Projectes

  • Ajuts per a la contractació de personal investigador novell (FI)
  • Predicción de micrometástasis en pacientes con cáncer de colon localizado de alto riesgo
  • Dimerizaciones de HER2 como elemento de decición en la terapia dirigida anti-HER2 frente al cáncer de mama
  • UTILITAT PRONOSTICA DELS PERFILS D'EXPRESSIO PROTEICA EN PACIENTS AMB TUMOR RESIDUAL VIABLE (>1.0 CM) DESPRES DE LA QUIMIOTERAPIA NEOADJUVANT EN CANCER DE MAMA
  • Cáncer de mama: utilidad pronóstica de los Perfiles de Expresión Proteica en pacientes con tumor residual viable (>1.0 cm) tras quimioterapia neoadyuvante